NCT04433845View on ClinicalTrials.gov

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

PHASE2UnknownINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

January 15, 2023

Study Completion Date

April 15, 2023

Conditions

Treatment Resistant Depression

Interventions

DRUG

Psilocybin

Open-label

Trial Locations (1)

21204

Sheppard Pratt, Baltimore

Sponsors

Collaborators (1)

COMPASS Pathways

All Listed Sponsors

collaborator

COMPASS Pathways

INDUSTRY

lead

Sheppard Pratt Health System

OTHER

NCT04433845 - The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. | Biotech Hunter | Biotech Hunter